Literature DB >> 11700420

Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock.

A Oldner1, D Konrad, E Weitzberg, A Rudehill, P Rossi, M Wanecek.   

Abstract

OBJECTIVE: Levosimendan is a novel inodilator that improves cardiac contractility by sensitizing troponin C to calcium. This drug has proved to be effective in treating advanced congestive heart failure but has not been evaluated in septic settings. The purpose of the present study was to study the effects of this drug in a porcine model of endotoxemia.
DESIGN: Prospective experimental study.
SUBJECTS: Fourteen landrace pigs.
INTERVENTIONS: All animals were anesthetized and catheterized for measurement of central and pulmonary hemodynamics. Ultrasonic flow probes were placed around the renal artery and portal vein to measure blood flow. A tonometer was placed in the ileum to measure mucosal pH. Levosimendan was given to six animals as a bolus (200 microg x kg(-1)) followed by a continuous infusion (200 microg x kg(-1) x hr(-1)). Thirty minutes after onset of levosimendan treatment, all animals received endotoxin (20 microg x kg(-1) x hr(-1) for 3 hrs).
MEASUREMENTS AND MAIN RESULTS: At baseline, levosimendan induced a systemic vasodilation with a reduction in blood pressure and an increase in heart rate. A tendency to an increase in cardiac index did not reach statistical significance (p =.055). Cardiac index and systemic oxygen delivery were markedly improved in the levosimendan group during endotoxemia. Systemic vascular resistance and blood pressure were reduced in the levosimendan group. The latter parameter, however, was only different from the control group during the initial phase of endotoxin shock but not at the late, most pronounced phase of shock. Levosimendan also efficiently attenuated endotoxin-induced pulmonary hypertension. Portal venous blood flow and gut oxygen delivery were improved, but no concomitant reduction in endotoxin-induced intestinal mucosal acidosis was observed. Renal blood flow was unaffected, as was the endotoxin-induced increase in plasma endothelin-1-like immunoreactivity. These findings support previous reports of calcium desensitization as a potential component in septic myocardial depression. Furthermore, the vasodilatory properties of this drug were well tolerated in the current model of hypodynamic endotoxin shock, and they may have contributed to improved regional blood flow as seen in the gut as well as improved systemic perfusion by means of reduced biventricular afterload.
CONCLUSION: Pretreatment with levosimendan in pigs subjected to endotoxin shock improved cardiac output and systemic and gut oxygen delivery. In addition, pulmonary hypertension largely was attenuated without any adverse effects on gas exchange. These results are promising in several aspects, but the role of levosimendan in the treating circulatory failure in sepsis remains to be established.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11700420     DOI: 10.1097/00003246-200111000-00022

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  20 in total

1.  Levosimendan in septic cardiac failure.

Authors:  A Noto; M Giacomini; A Palandi; L Stabile; C Reali-Forster; G Iapichino
Journal:  Intensive Care Med       Date:  2004-12-03       Impact factor: 17.440

2.  Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study.

Authors:  Arnaldo Dubin; Gastón Murias; Juan Pablo Sottile; Mario Omar Pozo; Marcelo Barán; Vanina Siham Kanoore Edul; Héctor Saúl Canales; Graciela Etcheverry; Bernardo Maskin; Elisa Estenssoro
Journal:  Intensive Care Med       Date:  2007-01-30       Impact factor: 17.440

3.  Levosimendan in septic shock: another piece in the puzzle, but many pieces are still lacking.

Authors:  Daniel De Backer; Fabio Silvio Taccone; Peter Radermacher
Journal:  Intensive Care Med       Date:  2007-01-30       Impact factor: 17.440

4.  Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression.

Authors:  Andrea Morelli; Stefano De Castro; Jean-Louis Teboul; Mervyn Singer; Monica Rocco; Giorgio Conti; Leonardo De Luca; Emanuele Di Angelantonio; Alessandra Orecchioni; Natesa G Pandian; Paolo Pietropaoli
Journal:  Intensive Care Med       Date:  2005-04-06       Impact factor: 17.440

Review 5.  [Role of Levosimendan in intensive care treatment of myocardial insufficiency].

Authors:  S Rehberg; C Ertmer; H Van Aken; M Lange; K Bröking; A Morelli; M Westphal
Journal:  Anaesthesist       Date:  2007-01       Impact factor: 1.041

6.  Single histidine button in cardiac troponin I sustains heart performance in response to severe hypercapnic respiratory acidosis in vivo.

Authors:  Nathan J Palpant; Louis G D'Alecy; Joseph M Metzger
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

Review 7.  Molecular cardiology in translation: gene, cell and chemical-based experimental therapeutics for the failing heart.

Authors:  Immanuel Turner; Fikru Belema-Bedada; Joshua Martindale; Dewayne Townsend; Wang Wang; Nathan Palpant; So-Chiro Yasuda; Matthew Barnabei; Ekaterina Fomicheva; Joseph M Metzger
Journal:  J Cardiovasc Transl Res       Date:  2008-12       Impact factor: 4.132

8.  The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts.

Authors:  Matthias Behrends; Jürgen Peters
Journal:  Intensive Care Med       Date:  2003-07-17       Impact factor: 17.440

9.  Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine.

Authors:  Joe Brierley; Joseph A Carcillo; Karen Choong; Tim Cornell; Allan Decaen; Andreas Deymann; Allan Doctor; Alan Davis; John Duff; Marc-Andre Dugas; Alan Duncan; Barry Evans; Jonathan Feldman; Kathryn Felmet; Gene Fisher; Lorry Frankel; Howard Jeffries; Bruce Greenwald; Juan Gutierrez; Mark Hall; Yong Y Han; James Hanson; Jan Hazelzet; Lynn Hernan; Jane Kiff; Niranjan Kissoon; Alexander Kon; Jose Irazuzta; Jose Irazusta; John Lin; Angie Lorts; Michelle Mariscalco; Renuka Mehta; Simon Nadel; Trung Nguyen; Carol Nicholson; Mark Peters; Regina Okhuysen-Cawley; Tom Poulton; Monica Relves; Agustin Rodriguez; Ranna Rozenfeld; Eduardo Schnitzler; Tom Shanley; Saraswati Kache; Sara Skache; Peter Skippen; Adalberto Torres; Bettina von Dessauer; Jacki Weingarten; Timothy Yeh; Arno Zaritsky; Bonnie Stojadinovic; Jerry Zimmerman; Aaron Zuckerberg
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

Review 10.  [Levosimendan. Clinical indications of a new vasoactive substance].

Authors:  J-P Braun; U Döpfmer; M Kastrup; I Roots; A Borges; M Schneider; P Dohmen; W Kox; C Spies
Journal:  Anaesthesist       Date:  2004-02       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.